Warner-lambert Company

Cayman Chemical Company Incorporated

Akos Biosciences, Inc.

Myometrics LLC

Thesan Pharmaceuticals, Inc.

Medicis Pharmaceutical Corporation

Graceway Pharmaceuticals, LLC

Fbm Therapeutics, LLC

James Bernard Kramer

Stephen Douglas Barrett

Gregory William Endres

Adam Uzieblo

Fred Lawrence Ciske

Bradlee David Germain

Joseph Michael Colombo

David T Connor

Andriy Kornilov

Diane H Boschelli

Kirk M Maxey

Huifen Chen

Mark Laurence Boys

Jagadish C Sircar

Paul C Unangst

Catherine R Kostlan

James Marino Hamby

Howard Daniel Hollis Showalter

James Paul O'Malley

Thomas Allen Owen

Daniel L Flynn

William Alexander Denny

Wiaczeslaw A Cetenko

Thomas R Belliotti

Yinghui Liu

Sonya Shah Khatana

Kirk William Hering

Paul M Hershberger

Ramanathan S Lalgudi

Peter Laurence Toogood

Annette Marian Doherty

Brian Desmond Palmer

Ellen Myra Dobrusin

Kirk Lang Olson

Pil Heui Lee

Andriy Komilov

Gordon William Rewcastle

Sylvester R Klutchko

Mel C Schroeder

William Howard Roark

Dennis Joseph McNamara

Howard D Showalter

Michael D Mullican

Richard Dennis Dyer

Susanne A Trumpp-Kallmeyer

Sony S Khatana

James Paul O'malley

Sylvester Klutchko

Disclosed are conjugate molecules formed from an active agent which is linked to a cannabinoid moiety through a specified linker having ester and amide end groups. The active agent can be a COX-2 inhibitor moiety, and the cannabinoid moiety can be a cannabidiol moiety. These conjugate molecules are contemplated to potentially be effective in the treatment of medical conditions.

Cannabinoid conjugate molecules

Disclosed herein are compounds of formula (I) and therapeutic methods of treatment with compounds of formula (I), wherein L, L, L, R, R, R, R, and s are as defined in the specification. Compounds of formula (I) are EP4 agonists useful in the treatment of glaucoma, neuropathic pain, and related disorders.

Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions

The present invention relates to processes and intermediates for preparing compounds of formula (IA), wherein R, R, R, R, and Lare as defined herein. Compounds of formula (IA) have been found useful as EPreceptor agonists useful in the treatment of glaucoma, osteoporosis, neuropathic pain, and related disorders. 

Methods of synthesizing a difluorolactam analog

The present invention relates to novel bone compositions for locally delivering a therapeutic agent to the site of a bone defect. Therapeutic agents may promote repair of the bone defect and/or treat conditions or disorders such as pain, inflammation, cancer, and infection. The compositions include calcium phosphate cements and a demineralized bone matrix or a collagen sponge. The compositions are useful for implantation in a patient at the site of a bone defect.

Methods, systems, and compositions for promoting bone growth

Difluorolactam compounds as EPreceptor-selective agonists for use in the treatment of EP-mediated diseases and conditions

The present invention provides for compounds of Formula I, and pharmaceutically acceptable salts thereof, wherein R, R, R, R, R, R, and Rhave any of the values defined therefor in the specification, and pharmaceutically acceptable salts thereof, that are useful as therapeutic agents in the treatment of TGF&#x3b2;-mediated conditions, including cancer and fibrotic disorders. Also provided are pharmaceutical compositions comprising one or more compounds of Formula I.

Therapeutic pyrazolyl thienopyridines

Disclosed herein are compositions and methods of treating osteroporosis, bone fracture, bone loss, and increasing bone density by administration of compounds of formula (I) or compositions comprising a compound of formula (I) and a pharmaceutically acceptable carrier, wherein L, L, L, R, R, R, R, and s are as defined in the specification.

[object Object]

Disclosed herein are compounds of formula (I) wherein L, L, L, L, R, R, R, R, and s are as defined in the specification. Compounds of formula (I) are EPagonists useful in the treatment of glaucoma, osteoporosis, bone fracture, periodontal bone loss, orthopedic implant, alopecia, neuropathic pain, and related disorders. Pharmaceutical compositions and methods of treating conditions or disorders are also described.

Disclosed herein are compositions and methods of treating osteoporosis, bone fracture, bone loss, and increasing bone density by administration of compounds of formula (I) or compositions comprising a compound of formula (I) and a pharmaceutically acceptable carrier, wherein L, L, L, R, R, R, R, and s are as defined in the specification.

Difluorolactam compositions for EP4-mediated osteo related diseases and conditions

Growing community of inventors

Sylvania, OH, United States of America

James Bernard Kramer